Search
Ripasudil
go.drugbank.com/drugs/DB13165InvestigationalThis medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec.
Coenzyme M
go.drugbank.com/drugs/DB09110ApprovedInvestigationalCoenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.[A18572]
Cefazolin
go.drugbank.com/drugs/DB01327ApprovedInvestigationalA semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.
Dextroamphetamine
go.drugbank.com/drugs/DB01576ApprovedIllicitInvestigationalDextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]
Teclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigational[L43612] Teclistamab was later granted accelerated approval by the FDA on October 25, 2022.[L43617]
Posaconazole
go.drugbank.com/drugs/DB01263ApprovedInvestigationalVet approvedPosaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
Valaciclovir
go.drugbank.com/drugs/DB00577ApprovedInvestigationalIt was initially approved by the FDA in 1995 [FDA label] and marketed by GlaxoSmithKline [L5671]. Valacyclovir is the L-valine ester of aciclovir. … It is caused by infection with the herpes simplex virus (HSV). Infection with this virus is lifelong with periodic episodes of reactivation [A175903].
Tick-borne encephalitis vaccine (whole virus, inactivated)
go.drugbank.com/drugs/DB16611ApprovedInvestigationalTick-borne encephalitis (TBE) is a disease caused by the TBE virus (TBEV), transmitted by ticks from the genus _Ixodes_. The disease course is variable. … [A237520] Originally developed by Baxter International Inc., TICOVAC was subsequently acquired by Pfizer Inc. in 2014.[L36120] TICOVAC was granted FDA approval on August 13, 2021.[L36050]
Ravulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigational[A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis. … [A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults.